Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter observational study of ustekinumab concentration and treatment efficacy in Crohn's disease
ChiCTR2400084547Phase 4Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in Crohn's disease, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Endoscopic SES-CD score at week 48. Started May 2024; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2400084547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084547.